

HAB HIV Core Clinical Performance Measures: Adult/Adolescent Clients Group 2



Performance Measure: Lipid Screening		OPR-Related Measure: No																					
Percentage of clients with HIV infection on HAART who had a fasting lipid panel ¹ during the measurement year																							
Numerator:	Number of HIV-infected clients who: <ul style="list-style-type: none"> • were prescribed HAART, and • had a fasting lipid panel in the measurement year 																						
Denominator:	Number of HIV-infected clients who are on HAART and who had a medical visit with a provider with prescribing privileges ² at least once in the measurement year																						
Patient Exclusions:	None																						
Data Element:	1. Is the client HIV-infected? (Y/N) <ul style="list-style-type: none"> a. If yes, was the client on HAART?(Y/N) <ul style="list-style-type: none"> i. If the client was on HAART, did he/she have a fasting lipid panel during the measurement year? (Y/N) 																						
Data Sources:	<ul style="list-style-type: none"> • Electronic Medical Record/Electronic Health Record • CAREWare, Lab Tracker, or other electronic data base • HIVQUAL reports on this measure for grantee under review • Medical record data abstraction by grantee of a sample of records 																						
National Goals, Targets, or Benchmarks for Comparison:	National HIVQUAL Data: ³ <table border="1" style="margin-left: 20px;"> <thead> <tr> <th></th> <th>2003</th> <th>2004</th> <th>2005</th> <th>2006</th> </tr> </thead> <tbody> <tr> <td>Top 10%</td> <td>100%</td> <td>100%</td> <td>100%</td> <td>100%</td> </tr> <tr> <td>Top 25%</td> <td>100%</td> <td>100%</td> <td>97.9%</td> <td>100%</td> </tr> <tr> <td>Mean*</td> <td>80.7%</td> <td>79.1%</td> <td>80.2%</td> <td>84.7%</td> </tr> </tbody> </table> <p><small>*From HAB database</small></p>				2003	2004	2005	2006	Top 10%	100%	100%	100%	100%	Top 25%	100%	100%	97.9%	100%	Mean*	80.7%	79.1%	80.2%	84.7%
	2003	2004	2005	2006																			
Top 10%	100%	100%	100%	100%																			
Top 25%	100%	100%	97.9%	100%																			
Mean*	80.7%	79.1%	80.2%	84.7%																			
Outcome Measures for Consideration:	<ul style="list-style-type: none"> ○ Incidence of cardiovascular events in clinic population ○ Incidence of metabolic syndrome in the clinic population 																						
Basis for Selection and Placement in Group 2:																							
<p>Changes in body shape, fat distribution & metabolism occur with frequency among HIV-infected patients, particularly those prescribed HAART. Metabolic changes that have been observed include hypertriglyceridemia, low high-density-lipoprotein (HDL) cholesterol and changes in LDL cholesterol.</p> <p>Although rates of prevalence vary, studies have found the rate of prevalence for metabolic syndrome to be almost 25% in a population of patients taking HAART⁴, where metabolic syndrome is defined as the presence of at least 3 of the following: hypertriglyceridemia, low high-density lipoprotein cholesterol, hypertension, abdominal obesity or high serum glucose.⁵</p> <p>All patients should receive a lipid profile at least once a year in order to monitor general health. For patients on HAART, lipid level monitoring is important to detect side effects and to identify patients who may require</p>																							

HAB HIV Core Clinical Performance Measures: Adult/Adolescent Clients Group 2



treatment.

Measure reflects important aspect of care that impacts HIV-related morbidity and focuses on treatment decisions that affect a sizable population. Measure has a strong evidence base supporting the use.

US Public Health Guidelines:

As part of pretreatment evaluation: “The following laboratory tests should be performed for each new patient during initial patient visits: ...and serum lipids if considered at risk for cardiovascular disease and for baseline evaluation prior to initiation of combination antiretroviral therapy (AIII)...”⁶

References/Notes:

¹A fasting lipid panel consists of fasting cholesterol, HDL, calculated LDL and triglycerides.

²A “provider with prescribing privileges” is a health care professional who is certified in their jurisdiction to prescribe ARV therapy.

³(<http://www.hivguidelines.org/admin/files/qoc/hivqual/proj%20info/HQNatlAggScrs3Yrs.pdf>) The HIVQUAL indicator includes all patients on ARV therapy.

⁴ Jacobson DL, Tang AM, Spiegelman D. Incidence of Metabolic Syndrome in a Cohort of HIV-Infected Adults and Prevalence Relative to the US Population (National Health and Nutrition Examination Survey).. [J Acquir Immune Defic Syndr](#). 2006 Sep 14

⁵ Jacobson DL, Tang AM, Spiegelman D. Incidence of Metabolic Syndrome in a Cohort of HIV-Infected Adults and Prevalence Relative to the US Population (National Health and Nutrition Examination Survey).. [J Acquir Immune Defic Syndr](#). 2006 Sep 14

⁶ Panel on Antiretroviral Guidelines for Adult and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-Infected Adults and Adolescents. Department of Health and Human Services. January 29, 2008, p. 3, 82. Available at <http://aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf> Accessed April 2, 2008.